Form 4: Veracyte SVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Veracyte's SVP and General Counsel, Annie McGuire, sold 10,739 shares of common stock on December 16, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Annie McGuire, SVP, General Counsel of Veracyte, Inc. (VCYT), reported transactions involving the sale of common stock.
- On December 16, 2025, McGuire sold a total of 10,739 shares of common stock.
- Specifically, 10,639 shares were sold at a weighted average price of $43.1277 per share, and an additional 100 shares were sold at $43.68 per share.
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025.
- Following these transactions, McGuire beneficially owns 67,760 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which typically indicates personal financial planning rather than a change in sentiment about the company's prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The sale of 10,739 shares by a senior executive represents a minor change in beneficial ownership and is unlikely to have a significant impact on the company's overall share structure or market perception, especially given it was pre-planned under a 10b5-1 plan.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 08/29/2025 | Rule 10b5-1 plan adopted by the reporting person. |
| 12/16/2025 | Date of common stock sales transactions. |
| 12/17/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe insider sale was conducted under a pre-arranged 10b5-1 plan, which typically signals personal financial planning rather than a change in the insider's view of the company's future performance. As such, this routine transaction does not provide new information to warrant a change in investment recommendation.
Keywords
Veracyte, VCYT, insider trading, Form 4, stock sale, Annie McGuire, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.